Floatz logo

Liraglutide

Feasibility

Anders Fink-Jensen, MD, DMSciprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Feasibility cohort.

Asset / SponsorPhaseRating
Rivoceranib
The University of Hong Kong-Shenzhen Hospital
D
LENVATINIB
The University of Hong Kong-Shenzhen Hospital
D
Sorafenib
The University of Hong Kong-Shenzhen Hospital
D

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
84 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →